US Stock MarketDetailed Quotes
STRO Sutro Biopharma
- 3.765
- +0.045+1.21%
Close Jul 19 16:00 ET
307.96MMarket Cap-2002P/E (TTM)
3.815High3.650Low518.91KVolume3.760Open3.720Pre Close1.95MTurnover0.86%Turnover RatioLossP/E (Static)81.79MShares6.13052wk High3.14P/B227.37MFloat Cap2.00552wk Low--Dividend TTM60.39MShs Float28.300Historical High--Div YieldTTM4.44%Amplitude2.005Historical Low3.751Avg Price1Lot Size
Sutro Biopharma Stock Forum
Sign in to post a comment
$Sutro Biopharma(STRO.US$ Completion of enrollment for Part One of the Phase II/III REFRaME-O1 trial for Luvelta and the anticipation of an update that could affirm its potential, which is estimated to be significantly greater than its competitor, Elahere, in platinum-resistant ovarian cancer (PROC). Bancroft highlights Luvelta’s ability to serve a wider PROC patient base, with the potential to address about 80% of patients expressing folate receptor alpha (FRα), in contr...
4
4
$Sutro Biopharma(STRO.US$ Sutro Biopharma Initiated at Buy by B of A Securities with a PT of 12.00!
Dow Jones· 2 mins ago
Dow Jones· 2 mins ago
See Biotech companies with cancer assets 👇
⇨ held by 5 biopharma-focused hedge funds! 🔥
$Arcellx(ACLX.US$ : Anito-cel (Ph 2)
$Adaptimmune Therapeutics(ADAP.US$ : Afami-cel (PDUFA) ⏳
$Bicycle Therapeutics(BCYC.US$ : BT8009 (Ph 1/2)
$Centessa Pharmaceuticals(CNTA.US$ : LB101 (Ph 1/2)
$Day One Biopharmaceuticals(DAWN.US$ : Tovorafenib (PDUFA) (check comments for details)
$Fate Therapeutics(FATE.US$ : FT576 (Ph 1)
$Fusion Pharmaceuticals(FUSN.US$ : FPI-2265 (Ph 2)
$GRCL: ...
⇨ held by 5 biopharma-focused hedge funds! 🔥
$Arcellx(ACLX.US$ : Anito-cel (Ph 2)
$Adaptimmune Therapeutics(ADAP.US$ : Afami-cel (PDUFA) ⏳
$Bicycle Therapeutics(BCYC.US$ : BT8009 (Ph 1/2)
$Centessa Pharmaceuticals(CNTA.US$ : LB101 (Ph 1/2)
$Day One Biopharmaceuticals(DAWN.US$ : Tovorafenib (PDUFA) (check comments for details)
$Fate Therapeutics(FATE.US$ : FT576 (Ph 1)
$Fusion Pharmaceuticals(FUSN.US$ : FPI-2265 (Ph 2)
$GRCL: ...
9
$Sutro Biopharma(STRO.US$ Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering
GlobeNewswire· 10 mins ago
GlobeNewswire· 10 mins ago
1
$Sutro Biopharma(STRO.US$ Sutro Biopharma Inc (STRO) has provided an announcement.
Sutro Biopharma, Inc. has secured a lucrative Exclusive License Agreement with Ipsen Pharma SAS to grant exclusive rights for the research, development, manufacture, and commercialization of STRO-003, a promising biopharmaceutical product. Ipsen has committed to an initial payment of $50 million and an investment of $25 million in Sutro Biopharma’s shares at a premium. Additional financial milestones includ...
Sutro Biopharma, Inc. has secured a lucrative Exclusive License Agreement with Ipsen Pharma SAS to grant exclusive rights for the research, development, manufacture, and commercialization of STRO-003, a promising biopharmaceutical product. Ipsen has committed to an initial payment of $50 million and an investment of $25 million in Sutro Biopharma’s shares at a premium. Additional financial milestones includ...
1
2
loading...
$Sutro Biopharma(STRO.US$ BUYERS MUST SELL ALL NOW AND NEVER BUY BACK, ENJOIN YOUR 💰💰💰🤩🤗🤩🤩🤩🤩💰
1
The low P/S ratio of Sutro Biopharma is attributed to its inferior revenue outlook and shareholders' pessimism about the company's future growth. The company's share price is unlikely to rise significantly in the near future due to these circumstances.
1
The lack of insider transactions in the last three months and low insider ownership in Sutro Biopharma is concerning. Investors should also note the company's 3 warning signs.
1
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
TrytosaveabitOP amiable Llama_6295: Yes it is! I sold for like 17% green! And haven’t got back in yet! It’s on my “ update look at your notes “ list! That I was supposed to look at this past weekend! Hehehe. But got busy doing stuff around the house! Hehehe. GL
Arrayfunction : Interesting this news caused so much of a kerfuffle. Getting the participants and starting phase II means they still haven't proved it actually works yet
TrytosaveabitOP Arrayfunction: The early data suggests, so far anyway, that it could end up being the standard for care? But yes if. And it a long way from that. But this is how it moves forward
Arrayfunction TrytosaveabitOP: You are definitely correct there! It's crazy how much of bio-tech is effectively just setting money on fire and hoping for the best!
My thoughts were more around the high risk approach they are taking running phase II/III at the same time. That signals to me either they are extremely confident about the drug based on unreleased efficacy data and want to double-time on getting it to market or the company has decided it is closing its doors regardless of the outcome (so either getting a patent to sell or going bankrupt)
The 2nd one is a lot more likely given the mountain of extra red tape running simultaneously adds - so not going near it as a long investor. But I hope your king of swing style can get some good returns on it!